Description
The mission of the Division of Oncology Immunotherapy is to develop and apply new immunotherapy strategies for the treatment of solid and hematologic cancers, closely linking clinical activity and scientific research.
Today, immunotherapy plays an increasingly important role in the treatment of various types of cancer. It is also emerging as a possible innovative option for patients who do not respond or are resistant to conventional therapies.
The Division works to promote research and rapidly transfer its results into clinical practice, with the goal of improving therapeutic outcomes and offering new treatment options.
The facility operates in close collaboration with the Department of Medical Oncology and the Transplantation and Cell Therapy Center, ensuring seamless integration of clinical and research activities.
The main clinical objectives are:
- Provide treatment, monitoring, and counseling programs for patients receiving immunotherapy
- Participate in and support clinical trials dedicated to new immunotherapy approaches
- Collect and analyze data to evaluate treatment efficacy and safety
Research objectives include:
- Investigate novel cellular therapies, including Tumor-infiltrating Lymphocytes TIL and CAR-killers, for cancers unresponsive to conventional treatments
- Design and conduct translational research studies to analyze immune system function in patients undergoing immunotherapy or other cancer therapies
How to book
Find out all the ways you can access services through the National Health Service, privately and through health funds and insurance coverage.
